Cas:468067-81-4 1H-Imidazole-2-carboximidamide,N-hydroxy-1-methyl manufacturer & supplier

We serve Chemical Name:1H-Imidazole-2-carboximidamide,N-hydroxy-1-methyl CAS:468067-81-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1H-Imidazole-2-carboximidamide,N-hydroxy-1-methyl

Chemical Name:1H-Imidazole-2-carboximidamide,N-hydroxy-1-methyl
CAS.NO:468067-81-4
Synonyms:N-hydroxy-1H-pyrrole-2-carboxamidine;N’-hydroxy-1H-benzimidazole-5-carboximidamide;N’-hydroxy-1-methyl-1H-imidazole-2-carboximidamide
Molecular Formula:C5H8N4O
Molecular Weight:140.14300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:76.43000
Exact Mass:140.07000
LogP:0.21490

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N-hydroxy-1H-pyrrole-2-carboxamidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N’-hydroxy-1-methyl-1H-imidazole-2-carboximidamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N’-hydroxy-1-methyl-1H-imidazole-2-carboximidamide Use and application,N-hydroxy-1H-pyrrole-2-carboxamidine technical grade,usp/ep/jp grade.


Related News: After speaking to iRhythm on Tuesday, J.P. Morgan analysts wrote we shouldn’t expect an update on reimbursement before the release of the Physician Fee Schedule proposed rule in July/August. 3,5-Dimethoxyphenylpropionic acid manufacturers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. 2-chloro-4-methylsulfonylphenol suppliers The CDC’s Advisory Committee on Immunization Practices (ACIP) decision on Thursday came after an hours-long discussion over a handful of Guillain-Barré syndrome (GBS) cases reported after J&J’s jab. The independent group of experts were also tasked with reviewing the need for booster shots, specifically for people with compromised immune systems. 5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carboxamide vendor & factory.